Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [1] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Denys, Hannelore
    Martinez-Mena, Corina L.
    Martens, Marc T.
    D'Hondt, Randal G.
    Graas, Marie-Pascale L.
    Evron, Ella
    Fried, Georgeta
    Ben-Baruch, Noa E.
    Vulsteke, Christof
    Van Steenberghe, Mona M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 97 - 105
  • [2] BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer
    Cocquyt, V. F.
    Martinez-Mena, C. L.
    Martens, M. T.
    D'Hondt, R. G.
    Graas, M-P L.
    Evron, E.
    Fried, G.
    Ben-Baruch, N. E.
    Dijkstra, A. C.
    Van De Walle, E. I.
    CANCER RESEARCH, 2017, 77
  • [3] Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study
    Talayeva, S.
    Kaidarova, D.
    Zhavrid, E.
    Prokharau, A.
    Antonenkova, N.
    Shatkovskaya, O.
    Manasheva, A.
    Rutzhanova, Z.
    BREAST, 2017, 32 : S27 - S27
  • [4] Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label randomized, multicenter, phase IIIB ESCAPE trial
    Kaidarova, Dilyara
    Zhavrid, Edvard
    Shatkovskaya, Oxana
    Prokharau, Aliaksandr
    Akhmed, Nina
    Sembayev, Dauren
    Rutzhanova, Zhanna
    Ivankov, Alexandr
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
  • [5] An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
    Cicin, Irfan
    Oukkal, Mohammed
    Mahfouf, Hassen
    Mezlini, Amel
    Larbaoui, Blaha
    Ben Ahmed, Slim
    Errihani, Hassan
    Alsaleh, Khalid
    Belbaraka, Rhizlane
    Yumuk, Perran Fulden
    Goktas, Burce
    Ozguroglu, Mustafa
    EUROPEAN JOURNAL OF BREAST HEALTH, 2022, 18 (01) : 63 - 73
  • [6] An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
    Woodward, Natasha
    De Boer, Richard H.
    Redfern, Andrew
    Von Neumann-Cosel, Vita
    Heath, Ronelle M.
    Beith, Jane
    CANCER RESEARCH, 2015, 75
  • [7] Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
    Pivot, Xavier
    Gligorov, Joseph
    Mueller, Volkmar
    Barrett-Lee, Peter
    Verma, Sunil
    Knoop, Ann
    Curigliano, Giuseppe
    Semiglazov, Vladimir
    Lopez-Vivanco, Guillermo
    Jenkins, Valerie
    Scotto, Nana
    Osborne, Stuart
    Fallowfield, Lesley
    LANCET ONCOLOGY, 2013, 14 (10): : 962 - 970
  • [8] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [9] ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS
    Jackisch, C.
    Dank, M.
    Frasci, G.
    Park, K. H.
    Lopez, R. I.
    Johnston, M.
    Heinzmann, D.
    Weber, H.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 103
  • [10] Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
    Woodward, N.
    De Boer, R. H.
    Redfern, A.
    White, M.
    Roberts, W.
    Truman, M.
    Beith, J.
    CANCER RESEARCH, 2017, 77
12345